Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05157087 · ClinicalTrials.gov registry record
XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States
A clinical trial, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- 16,246
- Enrollment target
NCT05157087: Completed study, sponsored by Novartis Pharmaceuticals.
NCT05157087 is a clinical trial that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 16,246 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05157087 has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- 16,246 participants
- Enrollment target
Study Summary
A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months
Primary Outcome
Uncontrolled asthma was based on either impairment or risk criteria in a 12- month consecutive period. * Impairment was identified as ≥6 Short-acting Beta Agonist (SABA) prescriptions dispensed in 12 months. Each prescription should reflect one month days supply. * Risk was defined as ≥1 unique exacerbation(s) in 12 months, including asthma-related ED visits or hospitalizations (emergency or hospital care with a diagnosis of asthma in the first position only \[ICD-9 code 493.xx, ICD-10 code J45
Interventions
- DRUG Omalizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16,246 participants |
| Start Date | 2020-03-01 |
| Est. Completion | 2020-12-01 |
What the finished NCT05157087 record still lists
NCT05157087 is an observational study that tracks outcomes without assigning an intervention. Its 16,246 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 1 intervention - of which Omalizumab is the first listed.
NCT05157087 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05157087 about?
NCT05157087 is a clinical study titled "XOLAIR (Omalizumab) Outcomes in Pediatric Allergic Asthma Patients in the United States". A retrospective database pre-post cohort study, identifying asthmatic patients, aged 6- 11, with omalizumab use over 24 months
What is the current status of trial NCT05157087?
This trial is currently completed. The enrollment target is 16,246 participants. The study started on 2020-03-01. Estimated completion is 2020-12-01.
What interventions are being tested in trial NCT05157087?
The interventions under investigation include: Omalizumab (DRUG).
Who is sponsoring clinical trial NCT05157087?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01737528 · 16,000 participants
STS/ACC Transcatheter Valve Therapy Registry (TVT Registry)
- NCT06380114 · 16,000 participants · NA
Stand Up 2 HPV: Standing Orders to Improve HPV Vaccination
- NCT06951867 · 16,640 participants
Tezspire Cardiac Events PASS
- NCT05447806 · 15,732 participants · NA
Diabetes Clinical Decision Support
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI